Fredrik Frejd, Chief Scientific Officer at Affibody, explains how the company’s radiotherapeutic candidate could address some of the limitations inherent in current approaches. The field of targeted radiopharmaceuticals has witnessed remarkable growth in recent years, driven by blockbuster successes of Novartis’ Lutathera (lutetium Lu 177 dotatate) and Pluvicto (lutetium Lu 177 vipivotide tetraxetan), which together generated over… Read More
New data on Molecular Partners’ radiotherapy candidate MP0712 shows targeted delivery into cancer tumours. MP0712 is being developed for the treatment of patients with small cell lung cancer (SCLC) and other neuroendocrine cancers. The candidate, which targets DLL3, showed potential to deliver radiotherapy treatment to tumours with… Read More
Akiram Therapeutics, a Swedish biotech company specialising in targeted radiotherapy, has enrolled the first patient in the Phase I clinical trial of its drug candidate 177Lu-AKIR001. The trial is being conducted at Karolinska University Hospital, which also acts as the study sponsor, and marks an important milestone in Akiram’s efforts… Read More
